<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35268400</PMID><DateRevised><Year>2022</Year><Month>03</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2077-0383</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><Issue>5</Issue><PubDate><Year>2022</Year><Month>Feb</Month><Day>27</Day></PubDate></JournalIssue><Title>Journal of clinical medicine</Title><ISOAbbreviation>J Clin Med</ISOAbbreviation></Journal><ArticleTitle>Serial Changes of Long COVID Symptoms and Clinical Utility of Serum Antibody Titers for Evaluation of Long COVID.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1309</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/jcm11051309</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Various symptoms persist even after the acute symptoms in about one third of patients with COVID-19. In February 2021, we established an outpatient clinic in a university hospital for patients with long COVID and started medical treatment for sequelae that persisted one month or more after infection.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">To determine the key factors that affect the onset and clinical course of sequelae, a retrospective analysis was performed at Okayama University Hospital (Japan) between February and July 2021. We focused on changes in the numbers of symptoms and the background of the patients during a three-month period from the first outpatient visit. We also examined the relationship with SARS-CoV-2 antibody titers.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Information was obtained from medical records for 65 patients. The symptoms of sequelae were diverse, with more than 20 types. The most frequent symptoms were general malaise, dysosmia, dysgeusia, sleeplessness, and headache. These symptoms improved in about 60% of the patients after 3 months. Patients who required hospitalization and had a poor condition in the acute phase and patients who received oxygen/dexamethasone therapy had higher antibody titers at the time of consultation. Patients with antibody titers &#x2265;200 U/mL showed significantly fewer improvements in long COVID symptoms in 1 month, but they showed improvements at 3 months after the first visit.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Long COVID symptoms were improved at 3 months after the initial visit in more than half of the patients. Serum antibody titers were higher in patients who experienced a severe acute phase, but the serum antibody titers did not seem to be directly related to the long-term persistence of long COVID symptoms.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sakurada</LastName><ForeName>Yasue</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sunada</LastName><ForeName>Naruhiko</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Honda</LastName><ForeName>Hiroyuki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tokumasu</LastName><ForeName>Kazuki</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Otsuka</LastName><ForeName>Yuki</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0001-6015-6128</Identifier><AffiliationInfo><Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakano</LastName><ForeName>Yasuhiro</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0001-9972-791X</Identifier><AffiliationInfo><Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hanayama</LastName><ForeName>Yoshihisa</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Furukawa</LastName><ForeName>Masanori</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, Okayama University Hospital, Okayama 700-8558, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hagiya</LastName><ForeName>Hideharu</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-5086-1891</Identifier><AffiliationInfo><Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Otsuka</LastName><ForeName>Fumio</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0001-7014-9095</Identifier><AffiliationInfo><Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Laboratory Medicine, Okayama University Hospital, Okayama 700-8558, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>02</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>J Clin Med</MedlineTA><NlmUniqueID>101606588</NlmUniqueID><ISSNLinking>2077-0383</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Anti-SARS-CoV2 antibody</Keyword><Keyword MajorTopicYN="N">dysgeusia</Keyword><Keyword MajorTopicYN="N">dysosmia</Keyword><Keyword MajorTopicYN="N">general fatigue</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>1</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>2</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>2</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>10</Day><Hour>15</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>2</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35268400</ArticleId><ArticleId IdType="pmc">PMC8911256</ArticleId><ArticleId IdType="doi">10.3390/jcm11051309</ArticleId><ArticleId IdType="pii">jcm11051309</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nuzzo J.B., Gostin L.O. The First 2 Years of COVID-19: Lessons to Improve Preparedness for the Next Pandemic. JAMA. 2022;327:217&#x2013;218. doi: 10.1001/jama.2021.24394.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.24394</ArticleId><ArticleId IdType="pubmed">34989763</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao Y.D., Ding M., Dong X., Zhang J.J., Kursat Azkur A., Azkur D., Gan H., Sun Y.L., Fu W., Li W., et al. Risk factors for severe and critically ill COVID-19 patients: A review. Allergy. 2021;76:428&#x2013;455. doi: 10.1111/all.14657.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/all.14657</ArticleId><ArticleId IdType="pubmed">33185910</ArticleId></ArticleIdList></Reference><Reference><Citation>Long L., Zeng X., Zhang X., Xiao W., Guo E., Zhan W., Yang X., Li C., Wu C., Xu T., et al. Short-term outcomes of COVID-19 and risk factors for progression. Eur. Respir J. 2020;55:2000990. doi: 10.1183/13993003.00990-2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.00990-2020</ArticleId><ArticleId IdType="pmc">PMC7173674</ArticleId><ArticleId IdType="pubmed">32312863</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang X., Li S., Yu H., Wang P., Zhang Y., Chen Z., Li Y., Cheng L., Li W., Jia H., et al. Epidemiological, comorbidity factors with severity and prognosis of COVID-19: A systematic review and meta-analysis. Aging (Albany NY) 2020;12:12493&#x2013;12503. doi: 10.18632/aging.103579.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/aging.103579</ArticleId><ArticleId IdType="pmc">PMC7377860</ArticleId><ArticleId IdType="pubmed">32658868</ArticleId></ArticleIdList></Reference><Reference><Citation>Setiati S., Harimurti K., Safitri E.D., Ranakusuma R.W., Saldi S.R.F., Azwar M.K., Marsigit J., Pitoyo Y., Widyaningsih W. Risk factors and laboratory test results associated with severe illness and mortality in COVID-19 patients: A systematic review. Acta Med. Indones. 2020;52:227&#x2013;245.</Citation><ArticleIdList><ArticleId IdType="pubmed">33020334</ArticleId></ArticleIdList></Reference><Reference><Citation>Graff K., Smith C., Silveira L., Jung S., Curran-Hays S., Jarjour J., Carpenter L., Pickard K., Mattiucci M., Fresia J., et al. Risk Factors for Severe COVID-19 in Children. Pediatr. Infect. Dis. J. 2021;40:e137&#x2013;e145. doi: 10.1097/INF.0000000000003043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0000000000003043</ArticleId><ArticleId IdType="pubmed">33538539</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahamat-Saleh Y., Fiolet T., Rebeaud M.E., Mulot M., Guihur A., El Fatouhi D., Laouali N., Peiffer-Smadja N., Aune D., Severi G. Diabetes, hypertension, body mass index, smoking and COVID-19-related mortality: A systematic review and meta-analysis of observational studies. BMJ Open. 2021;11:e052777. doi: 10.1136/bmjopen-2021-052777.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2021-052777</ArticleId><ArticleId IdType="pmc">PMC8557249</ArticleId><ArticleId IdType="pubmed">34697120</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiersinga W.J., Rhodes A., Cheng A.C., Peacock S.J., Prescott H.C. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020;324:782&#x2013;793. doi: 10.1001/jama.2020.12839.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12839</ArticleId><ArticleId IdType="pubmed">32648899</ArticleId></ArticleIdList></Reference><Reference><Citation>Brindisi G., De Vittori V., De Castro G., Duse M., Zicari A.M. Pills to think about in allergic rhinitis children during COVID-19 era. Acta Paediatr. 2020;109:2149&#x2013;2150. doi: 10.1111/apa.15462.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apa.15462</ArticleId><ArticleId IdType="pmc">PMC7361544</ArticleId><ArticleId IdType="pubmed">32627237</ArticleId></ArticleIdList></Reference><Reference><Citation>Carfi A., Bernabei R., Landi F., Gemelli against COVID-19 Post-Acute Care Study Group Persistent Symptoms in Patients After Acute COVID-19. JAMA. 2020;324:603&#x2013;605. doi: 10.1001/jama.2020.12603.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12603</ArticleId><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano J.B., Murthy S., Marshall J.C., Relan P., Diaz J.V., WHO Clinical Case Definition Working Group on Post-COVID-19 Condition A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2021 doi: 10.1016/S1473-3099(21)00703-9. in press .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00703-9</ArticleId><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah W., Hillman T., Playford E.D., Hishmeh L. Managing the long term effects of covid-19: Summary of NICE, SIGN, and RCGP rapid guideline. BMJ. 2021;372:n136. doi: 10.1136/bmj.n136.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n136</ArticleId><ArticleId IdType="pubmed">33483331</ArticleId></ArticleIdList></Reference><Reference><Citation>Anaya J.M., Rojas M., Salinas M.L., Rodriguez Y., Roa G., Lozano M., Rodriguez-Jimenez M., Montoya N., Zapata E., Post C.s.g., et al. Post-COVID syndrome. A case series and comprehensive review. Autoimmun. Rev. 2021;20:102947. doi: 10.1016/j.autrev.2021.102947.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2021.102947</ArticleId><ArticleId IdType="pmc">PMC8428988</ArticleId><ArticleId IdType="pubmed">34509649</ArticleId></ArticleIdList></Reference><Reference><Citation>Augustin M., Schommers P., Stecher M., Dewald F., Gieselmann L., Gruell H., Horn C., Vanshylla K., Cristanziano V.D., Osebold L., et al. Post-COVID syndrome in non-hospitalised patients with COVID-19: A longitudinal prospective cohort study. Lancet Reg. Health Eur. 2021;6:100122. doi: 10.1016/j.lanepe.2021.100122.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2021.100122</ArticleId><ArticleId IdType="pmc">PMC8129613</ArticleId><ArticleId IdType="pubmed">34027514</ArticleId></ArticleIdList></Reference><Reference><Citation>Otsuka Y., Nakano Y., Hagiya H., Tokumasu K., Otsuka F. Recovery From Alopecia after COVID-19. Cureus. 2022;14:e21160. doi: 10.7759/cureus.21160.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.21160</ArticleId><ArticleId IdType="pmc">PMC8831424</ArticleId><ArticleId IdType="pubmed">35165610</ArticleId></ArticleIdList></Reference><Reference><Citation>Parisi G.F., Diaferio L., Brindisi G., Indolfi C., Umano G.R., Klain A., Marchese G., Ghiglioni D.G., Zicari A.M., Marseglia G.L., et al. Cross-Sectional Survey on Long Term Sequelae of Pediatric COVID-19 among Italian Pediatricians. Children. 2021;8:769. doi: 10.3390/children8090769.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/children8090769</ArticleId><ArticleId IdType="pmc">PMC8467017</ArticleId><ArticleId IdType="pubmed">34572201</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A., Sehgal K., Gupta A., Madhavan M.V., McGroder C., Stevens J.S., Cook J.R., Nordvig A.S., Shalev D., Sehrawat T.S., et al. Post-acute COVID-19 syndrome. Nat. Med. 2021;27:601&#x2013;615. doi: 10.1038/s41591-021-01283-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Raveendran A.V., Jayadevan R., Sashidharan S. Long COVID: An overview. Diabetes Metab. Syndr. 2021;15:869&#x2013;875. doi: 10.1016/j.dsx.2021.04.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dsx.2021.04.007</ArticleId><ArticleId IdType="pmc">PMC8056514</ArticleId><ArticleId IdType="pubmed">33892403</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenhalgh T., Knight M., A&#x2019;Court C., Buxton M., Husain L. Management of post-acute covid-19 in primary care. BMJ. 2020;370:m3026. doi: 10.1136/bmj.m3026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m3026</ArticleId><ArticleId IdType="pubmed">32784198</ArticleId></ArticleIdList></Reference><Reference><Citation>Siso-Almirall A., Brito-Zeron P., Conangla Ferrin L., Kostov B., Moragas Moreno A., Mestres J., Sellares J., Galindo G., Morera R., Basora J., et al. Long Covid-19: Proposed Primary Care Clinical Guidelines for Diagnosis and Disease Management. Int. J. Environ. Res. Public Health. 2021;18:4350. doi: 10.3390/ijerph18084350.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph18084350</ArticleId><ArticleId IdType="pmc">PMC8073248</ArticleId><ArticleId IdType="pubmed">33923972</ArticleId></ArticleIdList></Reference><Reference><Citation>Otsuka Y., Tokumasu K., Nakano Y., Honda H., Sakurada Y., Sunada N., Omura D., Hasegawa K., Hagiya H., Obika M., et al. Clinical Characteristics of Japanese Patients Who Visited a COVID-19 Aftercare Clinic for Post-Acute Sequelae of COVID-19/Long COVID. Cureus. 2021;13:e18568. doi: 10.7759/cureus.18568.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.18568</ArticleId><ArticleId IdType="pmc">PMC8571943</ArticleId><ArticleId IdType="pubmed">34760415</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato Y. Case Management of COVID-19 (Secondary Version) JMA J. 2021;4:191&#x2013;197. doi: 10.31662/jmaj.2021-0036.</Citation><ArticleIdList><ArticleId IdType="doi">10.31662/jmaj.2021-0036</ArticleId><ArticleId IdType="pmc">PMC8355701</ArticleId><ArticleId IdType="pubmed">34414312</ArticleId></ArticleIdList></Reference><Reference><Citation>Infantino M., Pieri M., Nuccetelli M., Grossi V., Lari B., Tomassetti F., Calugi G., Pancani S., Benucci M., Casprini P., et al. The WHO International Standard for COVID-19 serological tests: Towards harmonization of anti-spike assays. Int. Immunopharmacol. 2021;100:108095. doi: 10.1016/j.intimp.2021.108095.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2021.108095</ArticleId><ArticleId IdType="pmc">PMC8403673</ArticleId><ArticleId IdType="pubmed">34619529</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaffner A., Risch L., Aeschbacher S., Risch C., Weber M.C., Thiel S.L., Jungert K., Pichler M., Grossmann K., Wohlwend N., et al. Characterization of a Pan-Immunoglobulin Assay Quantifying Antibodies Directed against the Receptor Binding Domain of the SARS-CoV-2 S1-Subunit of the Spike Protein: A Population-Based Study. J. Clin. Med. 2020;9:3989. doi: 10.3390/jcm9123989.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm9123989</ArticleId><ArticleId IdType="pmc">PMC7764650</ArticleId><ArticleId IdType="pubmed">33317059</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanda Y. Investigation of the freely available easy-to-use software &#x2018;EZR&#x2019; for medical statistics. Bone Marrow Transplant. 2013;48:452&#x2013;458. doi: 10.1038/bmt.2012.244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/bmt.2012.244</ArticleId><ArticleId IdType="pmc">PMC3590441</ArticleId><ArticleId IdType="pubmed">23208313</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyazato Y., Morioka S., Tsuzuki S., Akashi M., Osanai Y., Tanaka K., Terada M., Suzuki M., Kutsuna S., Saito S., et al. Prolonged and Late-Onset Symptoms of Coronavirus Disease 2019. Open Forum. Infect. Dis. 2020;7:ofaa507. doi: 10.1093/ofid/ofaa507.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofaa507</ArticleId><ArticleId IdType="pmc">PMC7665672</ArticleId><ArticleId IdType="pubmed">33230486</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Leon S., Wegman-Ostrosky T., Perelman C., Sepulveda R., Rebolledo P.A., Cuapio A., Villapol S. More than 50 long-term effects of COVID-19: A systematic review and meta-analysis. Sci. Rep. 2021;11:16144. doi: 10.1038/s41598-021-95565-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-95565-8</ArticleId><ArticleId IdType="pmc">PMC8352980</ArticleId><ArticleId IdType="pubmed">34373540</ArticleId></ArticleIdList></Reference><Reference><Citation>Bucciarelli V., Nasi M., Bianco F., Seferovic J., Ivkovic V., Gallina S., Mattioli A.V. Depression pandemic and cardiovascular risk in the COVID-19 era and long COVID syndrome: Gender makes a difference. Trends Cardiovasc. Med. 2022;32:12&#x2013;17. doi: 10.1016/j.tcm.2021.09.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tcm.2021.09.009</ArticleId><ArticleId IdType="pmc">PMC8490128</ArticleId><ArticleId IdType="pubmed">34619336</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasserie T., Hittle M., Goodman S.N. Assessment of the Frequency and Variety of Persistent Symptoms Among Patients With COVID-19: A Systematic Review. JAMA Netw. Open. 2021;4:e2111417. doi: 10.1001/jamanetworkopen.2021.11417.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.11417</ArticleId><ArticleId IdType="pmc">PMC8155823</ArticleId><ArticleId IdType="pubmed">34037731</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre C.H., Murray B., Varsavsky T., Graham M.S., Penfold R.S., Bowyer R.C., Pujol J.C., Klaser K., Antonelli M., Canas L.S., et al. Attributes and predictors of long COVID. Nat. Med. 2021;27:626&#x2013;631. doi: 10.1038/s41591-021-01292-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01292-y</ArticleId><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C., Huang L., Wang Y., Li X., Ren L., Gu X., Kang L., Guo L., Liu M., Zhou X., et al. 6-month consequences of COVID-19 in patients discharged from hospital: A cohort study. Lancet. 2021;397:220&#x2013;232. doi: 10.1016/S0140-6736(20)32656-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32656-8</ArticleId><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Abellan J., Padilla S., Fernandez-Gonzalez M., Garcia J.A., Agullo V., Andreo M., Ruiz S., Galiana A., Gutierrez F., Masia M. Antibody Response to SARS-CoV-2 is Associated with Long-term Clinical Outcome in Patients with COVID-19: A Longitudinal Study. J. Clin. Immunol. 2021;41:1490&#x2013;1501. doi: 10.1007/s10875-021-01083-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10875-021-01083-7</ArticleId><ArticleId IdType="pmc">PMC8285689</ArticleId><ArticleId IdType="pubmed">34273064</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>